Trial Profile
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms LDV/SOF ESRD
- Sponsors Gilead Sciences
- 01 Sep 2021 Primary endpoint (Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event) has been met, according to Results published in the American Journal of Gastroenterology.
- 01 Sep 2021 Primary endpoint (Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)) has been met, according to Results published in the American Journal of Gastroenterology.
- 01 Sep 2021 Results published in the American Journal of Gastroenterology.